Amir Ezzati Kaklar, Parviz Vahdani and Sara Taravati
The purpose of this study was to determine the effects of lamivudine and recombinant hepatitis B vaccine on chronic hepatitis B carriers. Studies has been shown that in animal models chronic Hepatitis B Vaccination can enhance immune response. Furthermore, treatment with lamivudine has resulting contributes to the maintenance of cellular immune responses than hepatitis antigen B. In this study, a group of eligible patients were divided into three groups. Lamivudine therapy and Vaccination were done in groups 1. In groups 2 lamivudine were used alone. In addition, The third group were used as control. The Fisher exact test was used for data analysis and differences among treatment in this study. The results showed that the only significant difference in the HBs Ag sreoconversion rates were observed between groups 1and control groups at the end of the fifteenth month. The present investigation suggested that the adjuvant therapy with hepatitis B vaccine together with lamivudine in chronic carriers of hepatitis B may lead to the eradication of viral infection in these patients
